REPCF (0913693 BC) Total Premiums Earned

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is 0913693 BC Total Premiums Earned?

Total Premiums Earned only applies to insurance companies.

0913693 BC Business Description

Address 570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1
RepliCel Life Sciences Inc. is a Canadian regenerative medicine company focused on developing autologous cell therapies for applications in orthopedics and aesthetics. Its pipeline includes RCT-01 for chronic tendon injuries, RCS-01 for skin rejuvenation, and RCH-01 for androgenetic alopecia, along with DermaPrecise, a proprietary injection device for precise dermal delivery. The company's therapies are based on its cell replication technology, using a patient's own cells to address functional cellular deficits. RepliCel operates as a single reportable business segment and has historically pursued a royalty-based model, licensing its technology to partners who commercialize the resulting products in exchange for royalty payments. Its target markets are primarily North America, Europe, and Asia, where demand for orthopedic and aesthetic treatments is significant. The company is headquartered in Canada and trades on Canadian and U.S. exchanges.